Effect of GWAS-Identified Genetic Variants on Maximum QT Interval in Patients with Schizophrenia Receiving Antipsychotic Agents

Journal of Clinical Psychopharmacology

Volumn 37, Issue 4, 2017, Pages 452-455

  Watanabe, Junzo ^a,b   Fukui, Naoki ^a   Suzuki, Yutaro ^a   Sugai, Takuro ^a   Ono, Shin ^a   Tsuneyama, Nobuto ^a   Saito, Mami ^a   Tajiri, Misuzu ^a   Someya, Toshiyuki ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b Niigata Kouseiren Nakajo Daini Hospital   (Japan)

Author keywords

24 hour Holter electrocardiogram; antipsychotic agents; genome wide association study; QT prolongation; schizophrenia

Indexed keywords

ARIPIPRAZOLE; BROMPERIDOL; CHLORPROMAZINE; FAMOTIDINE; FLUPHENAZINE; GENOMIC DNA; HALOPERIDOL; LANSOPRAZOLE; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PEROSPIRONE; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZOTEPINE;

ADULT; ALLELE; ARTICLE; BODY MASS; FEMALE; GENE FREQUENCY; GENETIC RISK; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETIC VARIANT; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; QTC INTERVAL; RR INTERVAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; AMBULATORY ELECTROCARDIOGRAPHY; DRUG EFFECTS; GENETIC VARIATION; GENETICS; HEART RATE; MIDDLE AGED; PROCEDURES; TIME FACTOR; TRENDS;

ADULT; ANTIPSYCHOTIC AGENTS; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HEART RATE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; TIME FACTORS;

EID: 85020267603     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000724     Document Type: Article

References (21)

1. Beach SR, Celano CM, Noseworthy PA, et al. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013;54:1-13.
2. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl JMed. 2009;360: 225-235.
3. Itoh H, Sakaguchi T, Ding WG, et al. Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome. Circ Arrhythm Electrophysiol. 2009;2:511-523.
4. Paulussen AD, Gilissen RA, Armstrong M, et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J MolMed (Berl). 2004;82: 182-188.
5. Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002;105: 1943-1948.
6. Newton-Cheh C, Eijgelsheim M, Rice KM, et al. Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet. 2009; 41:399-406.
7. Pfeufer A, Sanna S, Arking DE, et al. Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet. 2009; 41:407-414.
8. Browne KF, Prystowsky E, Heger JJ, et al. Prolongation of the Q-T interval in man during sleep. Am J Cardiol. 1983;52:55-59.
9. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64:663-667.
10. Watanabe J, SuzukiY, Fukui N, et al. Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour Holter electrocardiogram recording study. J Clin Psychopharmacol. 2012;32:18-22.
11. Fridericia LS. Die systolendauer im elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Med Scand. 1920;53:469-486.
12. Haga H, Yamada R, Ohnishi Y, et al. Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190, 562 genetic variations in the human genome. Single-nucleotide polymorphism. J Hum Genet. 2002;47:605-610.
13. Hirakawa M, Tanaka T, Hashimoto Y, et al. JSNP: a database of common gene variations in the Japanese population. Nucleic Acids Res. 2002;30: 158-162.
14. Fukui N, Suzuki Y, Sawamura K, et al. Dose-dependent effects of the 3435 C > T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther Drug Monit. 2007;29: 185-189.
15. Roden DM. Long QT syndrome: reduced repolarization reserve and the genetic link. J InternMed. 2006;259:59-69.
16. Qu X, Jia H, Garrity DM, et al. Ndrg4 is required for normal myocyte proliferation during early cardiac development in zebrafish. Dev Biol. 2008;317:486-496.
17. Nattel S, Maguy A, Le Bouter S, et al. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev. 2007;87:425-456.
18. Tsuji Y, Hojo M, Voigt N, et al. Ca(2+)-related signaling and protein phosphorylation abnormalities play central roles in a new experimental model of electrical storm. Circulation. 2011;123:2192-2203.
19. Aberg K, Adkins DE, Liu Y, et al. Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics J. 2012;12:165-172.
20. Kääb S, Crawford DC, Sinner MF, et al. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet. 2012;5:91-99.
21. Volpi S, Heaton C, Mack K, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry. 2009;14:1024-1031.